{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T07:32:40Z","timestamp":1789889560857,"version":"4.0.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bbrc.2026.154245","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:40:08Z","timestamp":1783352408000},"page":"154245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cooperative IFN-\u03b3 and TLR9 signaling reprogram tumor-associated macrophages to enhance antitumor immunity in melanoma"],"prefix":"10.1016","volume":"831","author":[{"given":"Toan","family":"Van Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0019-2076","authenticated-orcid":false,"given":"Ruslan","family":"Deviatiiarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8849-6239","authenticated-orcid":false,"given":"Yamano","family":"Tomoyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6203-9758","authenticated-orcid":false,"given":"Oleg","family":"Gusev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8075-5918","authenticated-orcid":false,"given":"Sofia","family":"Dubovskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngoc Lan Thi","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2102-3386","authenticated-orcid":false,"given":"Rikinari","family":"Hanayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9162-6795","authenticated-orcid":false,"given":"Tuan Duc","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.154245_bib1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/1479-5876-9-216","article-title":"Identification and manipulation of tumor associated macrophages in human cancers","volume":"9","author":"Heusinkveld","year":"2011","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.bbrc.2026.154245_bib2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/path.4824","article-title":"CAFs and TAMs: maestros of the tumour microenvironment","volume":"241","author":"Komohara","year":"2017","journal-title":"J. Pathol."},{"issue":"7","key":"10.1016\/j.bbrc.2026.154245_bib3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumor-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bbrc.2026.154245_bib4","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nri3073","article-title":"Protective and pathogenic functions of macrophage subsets","volume":"11","author":"Murray","year":"2011","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.bbrc.2026.154245_bib5","doi-asserted-by":"crossref","first-page":"R246","DOI":"10.1016\/j.cub.2020.01.031","article-title":"Tumor-associated macrophages","volume":"30","author":"Cassetta","year":"2020","journal-title":"Curr. Biol."},{"issue":"10","key":"10.1016\/j.bbrc.2026.154245_bib6","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/ni.1937","article-title":"Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm","volume":"11","author":"Biswas","year":"2010","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.bbrc.2026.154245_bib7","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bbrc.2026.154245_bib8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.immuni.2005.02.003","article-title":"Primary antitumor immune response mediated by CD4+ T cells","volume":"22","author":"Corthay","year":"2005","journal-title":"Immunity"},{"issue":"15","key":"10.1016\/j.bbrc.2026.154245_bib9","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1158\/0008-5472.CAN-19-0761","article-title":"Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy","volume":"79","author":"Zhang","year":"2019","journal-title":"Cancer Res."},{"issue":"6024","key":"10.1016\/j.bbrc.2026.154245_bib10","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science."},{"issue":"7645","key":"10.1016\/j.bbrc.2026.154245_bib11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nature21409","article-title":"Class IIa HDAC inhibition reduces breast tumors and metastases via anti-tumor macrophages","volume":"543","author":"Guerriero","year":"2017","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.bbrc.2026.154245_bib12","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nri3088","article-title":"Transcriptional regulation of macrophage polarization: enabling diversity with identity","volume":"11","author":"Lawrence","year":"2011","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.bbrc.2026.154245_bib13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","article-title":"The JAK-STAT pathway at twenty","volume":"36","author":"Stark","year":"2012","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.bbrc.2026.154245_bib14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1089\/jir.2018.0087","article-title":"The interferon-gamma paradox in cancer","volume":"39","author":"Zaidi","year":"2019","journal-title":"J. Interferon Cytokine Res."},{"issue":"2","key":"10.1016\/j.bbrc.2026.154245_bib15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-\u03b3: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J. Leukoc. Biol."},{"issue":"10","key":"10.1016\/j.bbrc.2026.154245_bib16","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.bbrc.2026.154245_bib17","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.bbrc.2026.154245_bib18","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2026.154245_bib19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","article-title":"Toll-like receptor signaling pathways","volume":"5","author":"Kawasaki","year":"2014","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.bbrc.2026.154245_bib20","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.4049\/jimmunol.171.8.3941","article-title":"Intratumor CpG-Oligodeoxynucleotide injection induces protective antitumor T cell Immunity1","volume":"171","author":"Lonsdorf","year":"2003","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.bbrc.2026.154245_bib21","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.4049\/jimmunol.1101304","article-title":"Intra-tumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells","volume":"188","author":"Shirota","year":"2012","journal-title":"J. Immunol."},{"issue":"17","key":"10.1016\/j.bbrc.2026.154245_bib22","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1002\/cncr.24473","article-title":"Randomized phase 2\/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma","volume":"115","author":"Weber","year":"2009","journal-title":"Cancer."},{"issue":"5","key":"10.1016\/j.bbrc.2026.154245_bib23","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1172\/JCI31414","article-title":"Development of TLR9 agonists for cancer therapy","volume":"117","author":"Krieg","year":"2007","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.bbrc.2026.154245_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2013.08.009","article-title":"Synergistic activation of inflammatory cytokine genes by Interferon-\u03b3-induced chromatin remodeling and toll-like receptor signaling","volume":"39","author":"Qiao","year":"2013","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.bbrc.2026.154245_bib25","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1038\/s41467-019-11147-3","article-title":"IFN-\u03b3 selectively suppresses a subset of TLR4-activated genes and enhancers to potentiate macrophage activation","volume":"10","author":"Kang","year":"2019","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.bbrc.2026.154245_bib26","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1359\/jbmr.2000.15.8.1477","article-title":"Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts","volume":"15","author":"Takeshita","year":"2000","journal-title":"J. Bone Miner. Res."},{"issue":"76","key":"10.1016\/j.bbrc.2026.154245_bib27","doi-asserted-by":"crossref","DOI":"10.3791\/50323-v","article-title":"Investigation of macrophage polarization using bone marrow derived macrophages","author":"Ying","year":"2013","journal-title":"J. Vis. Exp."},{"issue":"1","key":"10.1016\/j.bbrc.2026.154245_bib28","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41467-018-08126-5","article-title":"C1 CAGE detects transcription start sites and enhancer activity at single-cell resolution","volume":"10","author":"Kouno","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbrc.2026.154245_bib29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s44161-022-00182-x","article-title":"An atlas of transcribed human cardiac promoters and enhancers reveals an important role of regulatory elements in heart failure","volume":"2","author":"Deviatiiarov","year":"2023","journal-title":"Nat. Cardiovasc. Res."},{"key":"10.1016\/j.bbrc.2026.154245_bib30","doi-asserted-by":"crossref","DOI":"10.1177\/117793220800200004","article-title":"IMAGE: a new tool for the prediction of transcription factor binding sites","volume":"2","author":"Casilli","year":"2008","journal-title":"Bioinf. Biol. Insights"},{"key":"10.1016\/j.bbrc.2026.154245_bib31","first-page":"1438","article-title":"From reads to genes to pathways: differential expression analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline","volume":"5","author":"Chen","year":"2016","journal-title":"F1000Res"},{"issue":"7493","key":"10.1016\/j.bbrc.2026.154245_bib32","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nature12787","article-title":"An atlas of active enhancers across human cell types and tissues","volume":"507","author":"Andersson","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154245_bib33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13059-018-1519-9","article-title":"The 3D genome browser: a web-based browser for visualizing 3D genome organization and long-range chromatin interactions","volume":"19","author":"Wang","year":"2018","journal-title":"Genome Biol."},{"issue":"8","key":"10.1016\/j.bbrc.2026.154245_bib34","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/ni.2622","article-title":"The nuclear receptor LXR\u03b1 controls the functional specialization of splenic macrophages","volume":"14","author":"A-Gonzalez","year":"2013","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.bbrc.2026.154245_bib35","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/hon.3050","article-title":"NR1H3 (LXR\u03b1) is associated with pro\u2010inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b\u2010cell lymphoma","volume":"40","author":"Vegliante","year":"2022","journal-title":"Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.bbrc.2026.154245_bib36","doi-asserted-by":"crossref","first-page":"6035","DOI":"10.4049\/jimmunol.1402521","article-title":"Batf2\/Irf1 induces inflammatory responses in classically activated macrophages, lipopolysaccharides, and mycobacterial infection","volume":"194","author":"Roy","year":"2015","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.bbrc.2026.154245_bib37","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3892\/ijmm.2016.2583","article-title":"Effects of IRF1 and IFN-\u03b2 interaction on the M1 polarization of macrophages and its antitumor function","volume":"38","author":"Xie","year":"2016","journal-title":"Int. J. Mol. Med."},{"issue":"6225","key":"10.1016\/j.bbrc.2026.154245_bib38","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.1259418","article-title":"Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells","volume":"347","author":"Arner","year":"2015","journal-title":"Science."},{"key":"10.1016\/j.bbrc.2026.154245_bib39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1749-6632.2009.05069.x","article-title":"Clinical use of Interferon-\u03b3","volume":"1182","author":"Miller","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"8","key":"10.1016\/j.bbrc.2026.154245_bib40","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"200","key":"10.1016\/j.bbrc.2026.154245_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-Regulation of PD-L1, IDO, and tregs in the melanoma tumor microenvironment is driven by CD8+ T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.bbrc.2026.154245_bib42","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","article-title":"Interferon-\u03b3: teammate or opponent in the tumour microenvironment?","volume":"22","author":"Gocher","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.bbrc.2026.154245_bib43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/biomedicines2030211","article-title":"Toll-like receptor 9 agonists for cancer therapy","volume":"2","author":"Melisi","year":"2014","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.bbrc.2026.154245_bib44","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1080\/14737140.2021.1915136","article-title":"Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy","volume":"21","author":"Jin","year":"2021","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.bbrc.2026.154245_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-Gamma at the crossroads of tumor immune surveillance or evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbrc.2026.154245_bib46","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1038\/s41467-023-40028-z","article-title":"A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors","volume":"14","author":"Zibelman","year":"2023","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.bbrc.2026.154245_bib47","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/s41416-022-01876-6","article-title":"Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity","volume":"127","author":"Dongye","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2026.154245_bib48","doi-asserted-by":"crossref","first-page":"10039","DOI":"10.2147\/OTT.S247050","article-title":"Toll-like receptor 9 agonists in cancer","volume":"13","author":"Karapetyan","year":"2020","journal-title":"OncoTargets Ther."},{"issue":"4","key":"10.1016\/j.bbrc.2026.154245_bib49","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/eji.201445132","article-title":"TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN","volume":"45","author":"Temizoz","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bbrc.2026.154245_bib50","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ebiom.2017.07.011","article-title":"Induction of live cell phagocytosis by a specific combination of inflammatory stimuli","volume":"22","author":"Ishidome","year":"2017","journal-title":"EBioMedicine"},{"issue":"20","key":"10.1016\/j.bbrc.2026.154245_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012499","article-title":"Targeting CXCR4 and CD47 receptors: an overview of new and old molecules for a biological personalized anticancer therapy","volume":"23","author":"Leo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"17","key":"10.1016\/j.bbrc.2026.154245_bib52","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1073\/pnas.1121623109","article-title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"6","key":"10.1016\/j.bbrc.2026.154245_bib53","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1172\/JCI43157","article-title":"Repeated TLR9 stimulation results in macrophage activation syndrome\u2013like disease in mice","volume":"121","author":"Behrens","year":"2011","journal-title":"J. Clin. Investig."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26010090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26010090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:35:15Z","timestamp":1787070915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26010090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":53,"alternative-id":["S0006291X26010090"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154245","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cooperative IFN-\u03b3 and TLR9 signaling reprogram tumor-associated macrophages to enhance antitumor immunity in melanoma","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154245","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"154245"}}